Hexal Australia Pty Ltd v Roche Therapeutics Inc

Link copied
Case Copied 37 min read

FEDERAL COURT OF AUSTRALIA

Hexal Australia Pty Ltd v Roche Therapeutics Inc

[2005] FCA 1218

PATENTS – interlocutory injunctions – application for injunctions for threatened infringement of patent – claim that patent is invalid – lack of novelty – obviousness – lack of fair basis – whether serious issue to be tried – whether applicant for injunctions would suffer irreparable harm for which damages would not be adequate compensation unless an injunction is granted – balance of convenience – proposed applications for listing of pharmaceutical products on the Pharmaceutical Benefits Scheme – applications for injunctions refused

Federal Court of Australia Act 1976 (Cth), s 23
National Health Act 1953 (Cth)
Patents Act 1990 (Cth), ss 7, 40, 117
Patents Amendment Act 2001 (Cth)
Therapeutic Goods Act 1989 (Cth)

AB Hassle v Pharmacia (Australia) Pty Ltd (1995) 33 IPR 63 referred to
Aktiebolaget Hässle v Alphapharm Pty Ltd (2002) 212 CLR 411 cited
Aktiebolaget Hässle v Biochemie Australia Pty Ltd (2003) 57 IPR 1 cited
American Cyanamid v Ethicon Ltd [1975] AC 396 applied
Appleton Papers Inc v Tomasetti Paper Pty Ltd (1983) 3 NSWLR 208 cited
Bristol-Myers Squibb Co v FH Faulding & Co Ltd (2000) 97 FCR 524 discussed
Castlemaine Tooheys Ltd v The State of South Australia (1986) 161 CLR 148 applied
Evans Medical Ltd’s Patent [1998] RPC 517 referred to
General Tire & Rubber Company v Firestone Tyre and Rubber Co Ltd [1972] RPC 457 referred to
Hill v Evans (1862) 4 De GF & J 288; 45 ER 1195 referred to
ICI Chemicals & Polymers Ltd v The Lubrizol Corporation Inc (2000) 106 FCR 214 referred to
Jupiters Ltd v Neurizon Pty Ltd [2005] FCAFC 90 referred to
Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (2004) 217 CLR 274 referred to
Martin Engineering Co v Trison Holdings Pty Ltd (1988) 11 IPR 611 referred to
Merrell Dow Pharmaceuticals Inc v Norton & Co Ltd (1995) 33 IPR 1 referred to
Meyers Taylor Pty Ltd v Vicarr Industries Ltd (1977) 137 CLR 228 discussed
Olin Corporation v Super Cartridge Co Pty Ltd (1977) 180 CLR 236 referred to
Rehm Pty Limited v Websters Security Systems (International) Pty Limited (1989) 81 ALR 79 referred to
The Wellcome Foundation Ltd v VR Laboratories  (Aust) Pty Ltd (1981) 148 CLR 262 cited
Tidy Tea Ltd v Unilever Australia Ltd (1995) 32 IPR 405 referred to

Blanco White, Patents for Inventions, 4th ed, 1974

HEXAL AUSTRALIA PTY LTD v ROCHE THERAPEUTICS INC and F.HOFFMAN-LA ROCHE AG and ROCHE PRODUCTS AUSTRALIA PTY LTD
NSD 984 OF 2005

ROCHE THERAPEUTICS INC and F.HOFFMAN-LA ROCHE AG and ROCHE PRODUCTS AUSTRALIA PTY LTD v ALPHAPHARM PTY LTD
NSD 1209 OF 2005

STONE J
31 AUGUST 2005
SYDNEY

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

NSD 984 OF 2005

BETWEEN:

HEXAL AUSTRALIA PTY LTD
APPLICANT

AND:

ROCHE THERAPEUTICS INC
FIRST RESPONDENT

F.HOFFMAN-LA ROCHE AG
SECOND RESPONDENT

ROCHE PRODUCTS AUSTRALIA PTY LTD
THIRD RESPONDENT

JUDGE:

STONE…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Hexal Australia Pty Ltd v Roche Therapeutics Inc and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2005] FCA 1218
Decision Date

CaseChat Overview and Summary

Hexal Australia Pty Ltd and Alphapharm Pty Ltd applied for an interlocutory injunction against Roche Therapeutics Inc to prevent them from enforcing patent rights relating to the drug Pegasys. The dispute arose out of a contention that the patents held by Roche were invalid and that Hexal and Alphapharm intended to manufacture and sell a generic version of the drug. The case was heard in the Federal Court of Australia.

The court was required to decide whether Roche's patent rights were valid and whether an interlocutory injunction should be granted to prevent Hexal and Alphapharm from manufacturing and selling the drug. The court also had to consider the balance of convenience and whether the public interest in access to cheaper medicines outweighed Roche's right to enforce its patent.

The court found that there was a serious question to be tried in respect of infringement and that the concerns about invalidity probably had more weight. The court noted that Hexal and Alphapharm had not yet sold any products and that any loss to Roche would be comparatively easy to quantify. The court also considered the comparatively long delay to Hexal’s and Alphapharm’s plans and the availability of an early hearing. The court concluded that the balance of convenience favoured the refusal of the interlocutory relief sought by Roche.

The notice of motion filed on 1 July 2005 was dismissed, and the application for interlocutory relief was refused. The court emphasized that all parties must move with the utmost expedition towards an early hearing. Failure to do so might justify reviewing the decision.

Orders

Orders of the court

The notice of motion filed on 1 July 2005 be dismissed.

The application for interlocutory relief be refused.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

STONE J
Counsel for Hexal and Alphapharm also contended that the public interest was a relevant consideration. This entailed consideration of the public interest against the assertion of invalid patent rights and the public interest in having access to cheaper medicines, a probable result of the entry of Hexal and Alphapharm to the market. CONCLUSION In my view, the submissions on this issue are finely balanced. On the one hand, Hexal and Alphapharm have not, at this stage, sold any of their respective products and, strictly speaking, that represents the status quo. However, it is accepted by all parties that Hexal and Alphapharm intend to apply for registration on the PBS and, presumably, to sell their respective products. Given the view I have reached in relation to the adequacy of damages, it is not strictly necessary to come to a conclusion on the balance of convenience. However, I am inclined to the view that the balance of convenience favours the refusal of the interlocutory relief sought by Roche. In thus concluding I have taken into account my assessment of the strength of the competing contentions of the parties. I have concluded in favour of Roche that there is a serious question to be tried in respect of infringement. However, the case also raises serious questions of invalidity. While I am not in a position to assess the merits of these claims I am of the opinion that the concerns about invalidity probably have more weight. Taking into account the comparatively long delay to Hexal’s and Alphapharm’s plans, the fact that loss caused by interference with those plans would be particularly difficult to assess, the fact that any loss to Roche would be comparatively easy to quantify and the availability of an early hearing, I conclude that the balance of convenience dictates that interlocutory relief should be refused. This conclusion is predicated on the assumption that all parties will move with the utmost expedition towards an early hearing. A failure to do so might well justify reviewing this decision

Ratio Decidendi

Legal Principle Established

Established by: STONE J

Full text does not contain this section.